Skip to content

Clinical trials evaluating the efficacy and safety of GS1 continuous glucose monitoring systems

Clinical trials evaluating the efficacy and safety of GS1 continuous glucose monitoring systems

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073025
Enrollment
Unknown
Registered
2023-06-29
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Sponsors

Beijing Children's Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) Be between 3 years old (including 3 years old) and 18 years old (excluding 18 years old); (2) Clinical diagnosis of diabetes; (3) I and/or my guardian agree to participate in clinical trials and can sign informed consent as required; (4) The subjects are willing to wear the test equipment as required, and collect blood to detect blood glucose values according to the test requirements; (5) Subjects are willing to receive follow-up at the time specified in the trial.

Exclusion criteria

Exclusion criteria: (1) history of severe hypoglycemia in the past 6 months, defined as hypoglycemia leading to loss of consciousness or seizures; (2) Patients with heart failure and those with sequelae of hemiplegia in the past cerebrovascular disease; (3) The sensor wearing site has severe skin burns, burns, sunburns, trauma, ulcers, surgery and other scars; (4) Severe systemic skin lesions, such as extensive eczema, extensive scarring, extensive tattoos, herpetic dermatitis, severe edema, psoriasis and other cases that medical personnel believe affect the accuracy of the sensor; (5) Abnormal coagulation function, such as abnormal prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB); (6) Anemia or abnormal hematocrit; (7) Those who have donated blood within the past six months; (8) Pregnant and lactating women (pregnancy in this test is defined as a positive urine pregnancy test and women who have had menarche); (9) Those who are participating in or have participated in other clinical trials within one month; (10) Magnetic resonance imaging (MRI) and computed tomography are required during the sensor wearing (CT) examiners; (11) Those who are allergic to medical adhesives or alcohol; (12) Any circumstances that the investigator considers to be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Accordance rate;Product usability questionnaire;Mean absolute relative difference;Proportion of Zone A+B of Consensus error grid;Proportion of Zone A+B of Clarke error grid;

Secondary

MeasureTime frame
Alarm accuracy;Sensor stability;Repeatability of sensors;

Countries

China

Contacts

Public ContactChunxiu Gong

Beijing Children's Hospital Affiliated to Capital Medical University

chunxiugong@163.com+86 133 7011 5001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026